News Hub | News Direct

Polarean Imaging "very excited" to announce brand new customer for XENOVIEW polariser

Polarean Imaging PLC

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) CEO Christopher von Jako speaks to Thomas Warner from Proactive after the medical imaging technology company announced its first de novo order for its XENOVIEW polariser. Von Jako explains that the latest order, from a renowned medical institution in the Northeast, represents a significant step as it is from a brand new customer. Von Jako, who took the helm in July, also highlights the company's work with Dutch multinational Philips, emphasising the seamless integration of their products, including FDA-approved MRI coils. This collaboration extends to training Philips' commercial staff in the U.S., promising further growth in 2024. Additionally, Polarean is pursuing strategic growth initiatives, including increasing utilisation of their technology at sites like Cincinnati Children's Hospital and the University of Missouri. The company is also focusing on expanding its footprint and establishing Medicare reimbursement, thus enhancing its financial viability. Another key initiative involves conducting a clinical trial for FDA approval to explore new lung functions, potentially revolutionising lung imaging technology. In terms of financials, von Jako expressed confidence in closing the funding gap by the third quarter of the next year, supported by strategic investors. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 21, 2023 06:55 AM Eastern Standard Time

Video

The 2023 VinFuture Prize honored four scientific works under the theme of "Boundless Unity"

Vingroup

HANOI, VIETNAM - Media OutReach Newswire - 21 December 2023 - The VinFuture Foundation has honored four scientific breakthroughs in 2023. The US$3 million Grand Prize was awarded to the "Invention in creating a sustainable platform for green energy through production with solar cells and storage with Lithium-ion batteries." Three VinFuture Special Prizes were awarded to "Invention and advancement of disease-resistant rice varieties", "The discovery of the ozone depletion mechanism in Antarctica", and "The discovery of the role of glucagon-like peptides-1 (GLP-1), paving the way for widely used treatments for diabetes and obesity." The 2023 VinFuture Prize Award Ceremony was broadcast live nationally on Vietnam National Television VTV1. The ceremony was graced with the presence of His Excellency Vo Van Thuong - the President of the Socialist Republic of Viet Nam, and leaders of domestic ministries and departments, international ambassadors, and eminent scientists from around the world. The four winning works surpassed nearly 1,400 impressive nominations originating from 90 countries and territories. These breakthroughs have a profound impact on the present and future of humanity in crucial fields such as green and sustainable energy, climate change response, sustainable agriculture, food security, and healthcare, impacting the lives of billions of people worldwide. Remarkably, all the projects share a common thread of collaboration between developed and developing countries, leveraging the diversity of different groundbreaking inventions. Through this, the awarded breakthroughs have created comprehensive technologies of global significance, contributing to the construction of a sustainable future for humanity. Speaking at the Award Ceremony, President Vo Van Thuong said: "With a global vision and a "Boundless Unity" approach, the VinFuture Prize recognizes and honors scientists who have outstanding research works. Innovative and groundbreaking technologies with high practical applications are crucial for enhancing people's lives and fostering connections within the worldwide scientific community. Since the first series of the award until now, the VinFuture Prize has consistently pursued its mission of "science for humanity" with a focus on the four core values: Equality, Global Reach, Sustainability, and Pioneering. It has achieved steady growth in quality, quantity, and diversity, as well as gained increasing international attention, influence, and reputation. The President also affirmed that: "The success of the VinFuture Prize as a well-deserved outcome of the founder's diligent and committed efforts. I express my appreciation and congratulations to the founders who established this Award." The 2023 VinFuture Grand Prize was awarded to four scientists: Prof. Martin Andrew Green (Australia), Prof. Stanley Whittingham (United States), Prof. Rachid Yazami (Morocco), and Prof. Akira Yoshino (Japan) for their breakthrough inventions in creating a sustainable platform for green energy through production with solar cells and storage with Lithium-ion batteries. The combination of these transformative projects spearheaded a revolution in sustainable green energy solutions for the modern world. Prof. Martin Green and his research team pioneered the Passive Emitter and Rear Contact (PERC) technology, elevating energy conversion efficiency from 15% to an impressive 25%. These advancements deliver exceptional utilities, even in regions with limited sunlight conditions. Since its mass production in 2012, PERC solar cells have commanded a significant 60% share of the global solar cell market. Meanwhile, the advent of Lithium-ion battery storage has extended the reach of energy consumption across all geographical regions and socioeconomic classes, providing widespread access to green and sustainable energy solutions. Lithium-ion batteries power 15 billion mobile devices and 26 million electric vehicles globally, thanks to the work of outstanding scientists: Prof. Stanley Whittingham, Prof. Rachid Yazami, Prof. Akira Yoshino, and the late Prof. John Goodenough. The award ceremony also paid tribute to and honored the late Prof. John Goodenough – a pioneering scientist whose invention enabled Lithium-ion batteries to be safely rechargeable for the first time, improving the efficiency and saving resources. The synergy of these two groundbreaking technological revolutions has promoted the widespread adoption and accessibility of clean energy in our everyday lives through the conversion of solar energy into electricity by PERC solar cells and storage by Lithium-ion battery. In addition to the Grand Prize, three Special Prizes, each valued at US$500,000, have been awarded to innovators with outstanding achievements in emerging fields, female innovators, and innovators from developing countries. The 2023 VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields is awarded to Prof. Daniel Joshua Drucker (Canada), Prof. Joel Francis Habener (United States), Prof. Jens Juul Holst (Denmark), and Assoc. Prof. Svetlana Mojsov (United States) for the "discovery of the role of glucagon-like peptide-1 (GLP-1), paving the way for widely used treatments for diabetes and obesity and stimulating emerging applications for neurodegenerative diseases". The 2023 VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields is awarded to Prof. Daniel Joshua Drucker (Canada), Prof. Joel Francis Habener (United States), Prof. Jens Juul Holst (Denmark), and Assoc. Prof. Svetlana Mojsov (United States) Their work lays the foundation for the treatment of many diseases, including type-2 diabetes, obesity, and short bowel syndrome, positively impacting more than 400 million people with type-2 diabetes, more than 1 billion people with obesity, and more than 3 million people with short bowel syndrome. In 2023, more than 20 million doses of GLP-1 drugs have been used in the world, with an impressive 6.7% increase in adoption. In addition, the discovery of the peptide's acting mechanism has promoted research and development of novel treatments for cardiovascular diseases and neurodegenerative diseases, such as Alzheimer's and Parkinson's, which are among the leading causes of death globally. The 2023 VinFuture Special Prize for Innovators from Developing Countries has honored Indian American Prof. Gurdev Singh Khush and Vietnamese Prof. Vo Tong Xuan for their significant contributions to the invention and advancement of disease-resistant rice varieties, ensuring global food security. Professor Khush pioneered the development of rice cultivars with pest resistance, short growth periods, and high yields, such as IR36 and IR64. Among them, IR64 and its descendants have been widely grown in many countries, including the Philippines, Indonesia, Bangladesh, and India, while IR36 is popular in the Mekong Delta of Vietnam, which is regularly plagued by pests. Thanks to the significant efforts of Prof. Vo Tong Xuan, IR36 and IR64 rice varieties are currently the most common in tropical Asia, helping to cut production costs, enhance yield, restrict pesticide use, and promote global agricultural sustainability. The 2023 VinFuture Special Prize for Female Innovators has honored Prof. Susan Solomon (United States) for the discovery of the ozone depletion mechanism in Antarctica, contributing to the establishment of the Montreal Protocol. Prof. Solomon gathered credible information about the unusually large hole in the ozone layer caused by chlorofluorocarbons (CFC) in Antarctica, laying the groundwork for proposing and bringing the Montreal Protocol to fruition. This is one of the most successful international accords in tackling global environmental concerns, contributing to a global agreement to phase out ozone-depleting compounds like CFCs. According to released data from 2016, the ozone hole has been reduced by more than 4 million square kilometers since its peak in 2000 and will entirely regenerate in the coming decades. The Montreal Protocol has made a substantial contribution to the protection of the global climate system and is expected to prevent an additional 100-200 billion tons of CO2 emissions by 2050, potentially reducing the global temperature increase from 2-5°C to 0.5°C by 2100. Commenting on the results of the 2023 VinFuture Prize, Professor Sir Richard Friend, VinFuture Prize Council Chair, stated, "We are very excited to have announced our new VinFuture Prize winners. They have all made huge advances in science and innovation, and these have had real global impact. The Grand Prize recognizes the pioneers in two of the critical technologies we need to achieve zero-carbon energy that are critical if we are to control global warming. The breadth of scope to bring science and innovation to benefit society is huge, as reflected by this year's three Special Prizes. The vision that the Founders set – to celebrate the potential for discovery and innovation to bring real benefits to societies across the whole globe – is very clearly delivered in the set of this year's prize winners." The spirit of "Boundless Unity" for the benefit of humanity unites the four award-winning projects in a meaningful way. When individual scientific accomplishments synergize, they help to establish a sustainable foundation for humanity. The VinFuture Prize differs from other prestigious international awards in that it recognizes the cross-border collaboration of global scientists. With the success of the third award season, the VinFuture Prize upholds its reputation among the international scientific community owing to the comprehensiveness, diversity, and fairness of the judging process. The VinFuture Foundation is proud to continue its mission of "Science for Humanity" and inspiring innovation in Vietnamese science and technology, contributing to a prosperous, equitable, and sustainable future for all people worldwide. About the VinFuture Prize The VinFuture Prize is the core activity of the VinFuture Foundation, a non-profit organization established on International Human Solidarity Day on December 20th, 2020, co-founded by billionaire Mr. Pham Nhat Vuong and his wife, Mrs. Pham Thu Huong. The VinFuture Prize aims to recognize transformative scientific and technological innovations capable of making significant positive changes in the lives of millions of people worldwide. 2024 VinFuture Prize Official Call for Nominations The fourth award season of the VinFuture Prize has now begun, following the 2023 VinFuture Prize's conclusion. An official call for nominations will be launched from 2:00 p.m. on January 9, 2024 to 2:00 p.m. on April 17, 2023, Hanoi time (GMT+7).The award honors advances in science and technology that are aligned with the United Nations' 17 Sustainable Development Goals (SDGs), such as eradicating poverty, ending hunger, improving health and quality of life, creating opportunities for progressive education, clean water, renewable energy, reducing inequality, and responding to climate change. Nominators can submit their nominations by logging into this portal: https://online.vinfutureprize.org/nomination. Contact Details Media Contact v.chidqd1@vingroup.net

December 21, 2023 04:02 AM Eastern Standard Time

Image

New Study From San Antonio Breast Cancer Symposium Proves Innovative Marker Makes It Easier for Physicians to Detect and Remove Cancer Than Ever Before

Endomag

Research presented at the San Antonio Breast Cancer Symposium (SABCS) has found that surgeons and radiologists are moving away from one of the oldest traditional methods for locating and removing breast cancer, in favour of newer and more innovative technologies. The seminal study found that since 2020, usage rates of the guidewire – the standard in breast cancer surgery for over 60 years - has fallen from 83% of physicians using the device, to just 18%. In comparison, the rise of a unique metallic seed called the Magseed® marker has seen its adoption levels soar to 49%, meaning it has replaced the guidewire as the most used method for cancer localization. Having gained FDA approval in 2015, the Magseed has helped over 250,000 patients worldwide to access minimally-invasive, wire-free breast cancer care. Gone are the days of a patient attending an early appointment to have a guidewire placed on the day of their surgery, and having to wait around the hospital until the time of operation. Now, patients have the option of the Magseed being placed into the cancerous tissue any time ahead of surgery, at a time that suits them, safe in the knowledge it won’t move and can be easily found when the surgery takes place at a later date. “This study demonstrates that the modern solutions to localization are providing such a vast improvement for patients and the physicians using them, that they have been able to be rapidly adopted across the hospital setting.” said Mr. James Harvey, Oncoplastic Breast Surgeon and author of the study presented at SABCS 2023. The study from SABCS also surveyed each of the participating surgeons and radiologists, to understand the quality of user experience for each of their chosen devices for localizing tumors. Participants were asked about a range of topics including the reliability of locating the device, accuracy of cancer removal and the logistical benefits that the technology provides to the hospital. Once again, the results showed a significant benefit in favour of the wire-free Magseed device. On average, radiologists gave the device 9/10 for overall satisfaction, while surgeons scored it 8/10. In comparison, the guidewire received 7/10 scores from both audiences. “This is the first study to demonstrate that radiologists and surgeons now find Magseed to be more effective in patient care and a significant improvement on prior technologies.” continued Mr. Harvey. It is also the first study to ascertain the advantages and disadvantages of each localization device against one another. The findings here could now have far-reaching implications for breast cancer treatment across the world. The shift towards Magseed as the preferred localization device indicates there is growing interest in new technologies that improve patient outcomes. The landscape is changing for breast surgery, and it’s helping to drive ongoing research and innovation in cancer care. -ENDS- Notes to Editors: In the study, participants were asked to rate a range of features on a scale from 1-10 (10 being the highest level of satisfaction). Please find poster attached alongside this press release. This iBRA-NET satisfaction study includes findings from 84 breast units (65% of all UK sites), and was published at the San Antonio Breast Cancer Symposium on 7th December 2023. The Sentimag platform, along with Magseed marker and Magtrace lymphatic tracer, was developed by Endomag and is distributed by Mammotome in North America. More than 450,000 women have now received a better standard of breast cancer surgery with Endomag’s technologies. The Sentimag® is in use at over 1,000 hospitals in more than 45 countries across the world. About Us At Endomag, we believe everyone deserves a better standard of cancer care. That’s why we design our magnetic technologies with both the clinician and patient in mind. Many leading hospitals across the world use our unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is. At the heart of the company’s technologies is the Sentimag® localization system. The Sentimag® system features a probe which works like a metal detector. When it is placed near the skin’s surface, it can detect Endomag’s magnetic seed marker (Magseed®) and liquid tracer (Magtrace®), for accurate lesion localization and sentinel lymph node biopsy procedures. Endomag’s technologies have already helped 450,000+ women worldwide to access more precise, and minimally invasive breast cancer treatment. Contact Details Endomag Mary Nicholls +44 1223 652540 mnicholls@endomag.com

December 20, 2023 10:50 AM Eastern Standard Time

Image

Protecting Yourself from Respiratory Illnesses this Holiday Season

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ZW6KvqOsf9M The holiday season is in full swing, and it's crucial to safeguard ourselves, our children, and our communities against respiratory illnesses like the outbreak we are seeing in China. Just when we thought it was safe to travel and gather for the holidays, pneumonia and RSV outbreaks here in the US and around the Globe are rising. With all the shopping, planning, cooking, and traveling, nobody wants to spend the holidays in bed sick or maybe even in the hospital fighting nasty viruses that continue to circle the globe. A nationwide media tour was conducted featuring President of the College of American Pathologists, Dr. Donald Karcher, sharing some tips on keeping you and your family safe when celebrating the holidays. Topics during the media tour that President of the College of American Pathologists, Dr. Donald Karcher, discussed included: · An understanding of exactly what is happening and how concerned we should be. · What can parents look for and do to mitigate the illness and the effect on the rest of the family, including elderly friends and relatives? · Why testing is still so important in corralling these illnesses. For more information, visit Newsroom.CAP.ORG Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 19, 2023 02:22 PM Eastern Standard Time

Video

Cardio Diagnostics’ Breakthrough Coronary Heart Disease Detection Test Published In The Journal Of The American Heart Association

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics (NASDAQ: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine, has published a potentially revolutionary study in the Journal of the American Heart Association (JAHA). Conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, the publication details the development and validation of PrecisionCHD, a pioneering artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD). Titled "The Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease," the article sheds light on Cardio Diagnostics’ progress in the field of cardiovascular medicine while showcasing PrecisionCHD’s ability to detect CHD with high sensitivity with a blood test and provide better testing access to underserved communities. Democratizing Access Traditional diagnostic methods for CHD, often inaccessible due to the need for specialized infrastructure, can be invasive and sometimes require exposure to ionizing radiation. Additionally, some of the tests are not sensitive to all forms of CHD and can be very costly, leaving millions of Americans without adequate and potentially lifesaving cardiac care. PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence (AI), along with personalized genetic and epigenetic information, to detect the presence of CHD. Those who read the JAHA publication will learn about the development and validation of the PrecisionCHD test in three independent cohorts totaling 2,516 individuals. The study was collaboratively conducted by researchers from Cardio Diagnostics, Intermountain Healthcare and the University of Iowa Hospitals and Clinics. PrecisionCHD uses the input from six methylation sensitive digital PCR (MSdPCR) assessments to determine the presence or absence of CHD. The article details the mapping of each of these MSdPCR assays to distinct modifiable drivers of CHD, through which clinicians are able to gain personalized insights into each patient’s CHD presentation. It also notes that because methylation is dynamic, clinicians can consider focused re-testing to determine the effectiveness of CHD therapy. “What's truly revolutionary about this approach is its ability to provide a more comprehensive, personalized snapshot of a patient's CHD drivers, allowing for early intervention and tailored treatment plans,” said Robert Philibert MD Ph.D., lead author and Chief Medical Officer of Cardio Diagnostics. “This is personal for me; seeing patients who previously had limited options for early diagnosis now have access to this state-of-the-art technology is a milestone in cardiac care.” For rural communities where access to specialized medical facilities is limited, the implications of this research are particularly relevant. With only a simple blood draw needed to complete a test, PrecisionCHD offers patients in underserved areas access to state-of-the-art cardiac assessments. PrecisionCHD can be administered in primary care or telemedicine settings, significantly reducing the need for patients to travel to distant specialized clinics. This level of availability marks a step forward toward mitigating healthcare disparities, especially in rural areas with limited resources and infrastructure. “Our commitment is to democratize access to essential cardiac care, particularly in rural areas where advanced diagnostic tools are scarce and cardiovascular specialists are even more rare,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “PrecisionCHD's remote accessibility and deployment capability in non-specialized settings are pivotal in achieving this goal.” After recently finalizing an Innovation Technology contract with Vizient, Inc. – the nation’s largest provider-driven healthcare performance improvement company – Cardio Diagnostics will have access to a customer base that encompasses 60% of hospitals and 97% of academic medical centers in the United States. Member institutions have the ability to purchase the PrecisionCHD test through Vizient’s Innovative Technology Program. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

December 19, 2023 09:25 AM Eastern Standard Time

Redx Pharma CEO reports "good progress across the board"

Redx Pharma PLC

Redx Pharma PLC (AIM:REDX) CEO Lisa Anson speaks to Thomas Warner from Proactive after the clinical-stage biotechnology company released its final audited results for the year to 30 September. Anson discusses the company's performance in 2023 and outlined its plans for 2024. She highlights the successful launch of a Phase 2 program for lead asset Zelasudil, aimed at treating idiopathic pulmonary fibrosis, a challenging lung condition. Additionally, Anson touches upon another promising asset targeting the same mechanism, which is poised to enter clinical trials next year following extensive preclinical work. On the financial front, despite a challenging year, Redx Pharma successfully raised £14.1 million, ensuring funding through September 2024. This financial stability is crucial for achieving key milestones, which Anson believes will be pivotal for the company's growth. Looking ahead to 2024, Anson anticipates significant developments, including the release of Phase 2 data in idiopathic pulmonary fibrosis and resolving FDA regulatory issues in the first half of the year. Moreover, the company aims to initiate a Phase 1 study for its RXC008 (ROCK) asset, which would ne the sixth time Redx Pharma has brought a drug into clinical trials. In addition to these advances, Redx Pharma is also focusing on kidney fibrosis and oncology programs, with plans to progress these into clinical stages by 2026. Anson also emphasises the potential for new partnerships, particularly in advancing their oncology program for GI cancers, highlighting Redx Pharma's strategic approach to collaboration and development. This interview underlines Redx Pharma's significant strides in 2023 and sets a promising outlook for 2024, positioning the company as a key player in the pharmaceutical industry. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 19, 2023 07:25 AM Eastern Standard Time

Video

News Release

Voyageur Pharmaceuticals takes major step forward announcing international expansion

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to discuss the recent announcement regarding its international expansion and third-party manufacturing for barium sulfate products in the radiology market marks a significant development for the company. Voyageur has signed its first distribution deal with an international company. This is a crucial step in expanding its reach beyond Canada and tapping into global healthcare markets. Willis told Proactive the third-party manufacturing initiative is a precursor to the Francis Creek project, which is expected to significantly reduce production costs for barium sulfate. This cost reduction could enhance the company's competitiveness and profitability. The company is on track to conduct a bankable feasibility study for the Francis Creek project in early 2024. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

December 18, 2023 03:24 PM Eastern Standard Time

Video

Nooro Knee Massager Reviews: Is It Worth Buying?

Renske Technologies

Have you ever found yourself grappling with persistent knee discomfort and wondered about the underlying reasons? Often, the culprit is the gradual erosion of the crucial cushioning within your knee joints, known as cartilage. This gradual wear and tear set the stage for a distressing phenomenon – bone-on-bone knee pain. This not only manifests as acute discomfort but also introduces unwelcome companions in the form of swelling and an unsettling, shaky sensation in your knees. The ramifications of this condition extend far beyond mere physical discomfort. Simple, everyday activities that were once taken for granted – like driving, climbing stairs, and even achieving a restful night's sleep – suddenly become surprisingly challenging. The pain becomes more than just a physical sensation; it transforms into a formidable barrier that robs you of the freedom to engage in activities that were once second nature. However, amidst these challenges, there is a beacon of hope – the Nooro Knee Massager. This innovative device emerges as a promising solution to break free from the clutches of chronic knee pain. By combining advanced technology with a thoughtful design, Nooro Knee Massager offers the potential to reverse the impact of cartilage wear and tear. It becomes not just a device but a pathway to reclaiming comfort and regaining the freedom to partake in activities that were once hindered by persistent knee pain. Imagine a life where driving, ascending stairs, and even enjoying a peaceful night's sleep are no longer fraught with discomfort. The Nooro Knee Massager holds the promise of transforming this vision into reality. It's not merely a product; it's a catalyst for change, offering a renewed sense of well-being and the prospect of a life unburdened by the constraints of chronic knee pain. Kindly embrace the hope that the Nooro Knee Massager brings – a hope for a future where your knees no longer dictate the limitations of your daily life. Does it really work as advertised? What Is Nooro Knee Massager? Introducing the Nooro Knee Massager – a revolutionary device designed to provide targeted relief and relaxation for your knees. Engineered with advanced technology and ergonomic design, this innovative knee massager aims to redefine the way we address knee discomfort and promote overall joint well-being. The Nooro Knee Massager is equipped with customizable massage modes, allowing users to tailor their experience based on individual preferences and specific therapeutic needs. Its sleek and compact design ensures portability, enabling users to enjoy soothing knee massages anytime, anywhere – whether at home, in the office, or on the go. Crafted with a focus on user comfort, the Nooro Knee Massager features adjustable straps to accommodate various knee sizes and ensure a snug fit during use. The device incorporates a combination of heat therapy and massage, providing a dual-action approach to alleviate tension, reduce stiffness, and enhance blood circulation around the knee joint. Powered by cutting-edge technology, the Nooro Knee Massager is user-friendly, with intuitive controls that make it easy to navigate through different settings. Its rechargeable battery ensures long-lasting use, making it a convenient and sustainable solution for those seeking regular knee relief. Whether you are an athlete recovering from intense workouts, an individual managing chronic knee issues, or someone simply looking to pamper and relax your knees after a long day, the Nooro Knee Massager stands out as a versatile and effective solution. Nooro Knee Massager Consumer Appeal: The Combination of Three Effective Therapies Made through a collaboration with the US-based startup Nooro and spearheaded by the expertise of Dr. Jeremy, a distinguished bone specialist, the Nooro Knee Massager represents a groundbreaking advancement in knee care. This innovative device integrates three highly effective therapeutic approaches to address and alleviate persistent knee discomfort. Firstly, the inclusion of Red Light Therapy sets the Nooro Knee Massager apart. This therapy stimulates the natural production of collagen, a vital component in the regeneration of cartilage. By harnessing the power of red light, this massager aims to reverse cartilage damage, providing a proactive solution to a common source of knee pain. Complementing this, the Heat Therapy feature plays a pivotal role in promoting holistic healing. As the massager applies gentle heat, it effectively loosens muscles both around and within the knee joint. This not only enhances flexibility but also encourages improved blood circulation, fostering a conducive environment for faster healing. Heat therapy is a well-established method for addressing muscle and joint discomfort, and its integration into the Nooro Knee Massager adds a valuable dimension to its therapeutic capabilities. The third key element is Massage Therapy, an essential component in the quest for knee relief. By employing targeted massage techniques, this massager effectively relaxes tight muscles and tissues surrounding the knee. Beyond mere physical relaxation, this aspect of the therapy replaces the sensation of knee pain with a profound sense of relief, making the Nooro Knee Massager a comprehensive solution for individuals grappling with chronic knee discomfort. The overarching goal of the Nooro Knee Massager is to not merely provide symptomatic relief but to actively contribute to the restoration of cartilage, reduction of inflammation, and almost instantaneous pain relief. Its user-friendly design enhances its practicality, allowing users to effortlessly apply the massager by sliding it onto the affected knee, pushing the "on" button, and indulging in a targeted 15-minute therapy session. MUST SEE: Click Here Now To Get The Nooro Knee Massager Directly From The Official Website Features and Benefits (Nooro Knee Massager Reviews) Triple-Therapy Precision: Red Light Therapy: Stimulates collagen production, actively reversing cartilage damage. Heat Therapy: Loosens muscles and promotes blood flow for accelerated healing. Massage Therapy: Targeted relaxation of tight muscles, providing immediate relief. Collaborative Innovation: Developed in collaboration with Nooro, a US-based startup, and guided by Dr. Jeremy, a renowned bone specialist. Cartilage Restoration: Aims to restore and rejuvenate cartilage, addressing a fundamental source of knee pain. Non-Invasive Alternative: Offers a surgery-free solution, reducing the need for invasive interventions. User-Friendly Design: Easy application – simply slide onto the knee, push the "on" button, and enjoy a 15-minute targeted therapy session. Portable Convenience: Compact and portable, enabling use at home, in the office, or on the go. Fast Pain Relief: Provides almost instant relief, making it an effective solution for acute discomfort. Positive User Reviews: Garnered positive feedback for its transformative impact on chronic knee discomfort. Holistic Healing: Addresses not just symptoms but actively contributes to cartilage restoration, inflammation reduction, and overall knee health. Long-Lasting Battery: Rechargeable battery ensures prolonged use, enhancing sustainability. Customizable Modes: Adjustable settings allow users to tailor the experience to their preferences and therapeutic needs. Versatile Applications: Suitable for various knee sizes, accommodating a wide range of users. Does Nooro Knee Massager Really Work And Should You Buy It? In the realm of knee pain relief, the Nooro Knee Massager emerges as a formidable tool, addressing the core causes of joint discomfort with a foundation firmly rooted in rigorous scientific principles. This three-in-one massager harnesses the power of red light treatment, thermotherapy, and vibrations to provide a holistic solution for stabbing joint pain, numbness, and stiffness. Unlike conventional solutions, the Nooro Knee Massager is not merely a palliative measure but a scientifically backed intervention. Rigorous investigations support its efficacy, making it a trustworthy choice for individuals seeking genuine relief from persistent knee joint issues. The Nooro Knee Massager's prowess lies in its triple-threat approach. Red light treatment stimulates natural healing by addressing cartilage damage. Thermotherapy eases muscles and improves blood circulation, fostering an environment conducive to healing. Simultaneously, targeted vibrations offer a therapeutic massage, relaxing tight muscles and tissues around the knee. This massager not only alleviates pain but contributes to improved mobility. Users report relief from stabbing joint pain, numbness, and stiffness, highlighting the device's efficacy in enhancing overall knee function. The Nooro Knee Massager goes beyond symptomatic relief; it actively combats inflammation and swelling, providing a comprehensive solution to weariness associated with knee discomfort. Nooro Knee Massager Scam or Legit Consumer Reports? In the realm of knee pain relief, the Nooro Knee Massager has emerged as a beacon of hope for thousands, promising not just relief but a transformative journey towards enhanced knee health. As with any revolutionary product, skepticism often accompanies acclaim. One of the cornerstones of Nooro Knee Massager's credibility lies in its overwhelmingly positive user reviews. Numerous consumers have not only reported effective pain relief but have gone a step further, recommending the device to friends and relatives. The consensus among users is that the massager delivers on its promise of quick pain alleviation, debunking initial skepticism. Users suffering from various knee concerns, including stabbing knee pain, meniscus issues, and tendon concerns, have found solace in the Nooro Knee Massager. Its effectiveness extends beyond common knee ailments, showcasing its versatility in managing diverse pain-related challenges. The Nooro Knee Massager stands out as a cost-effective alternative to traditional solutions like surgery and therapy sessions. Its accessibility makes it an attractive choice, particularly for those seeking relief without the financial burden associated with other treatments. Backed by rigorous scientific testing spanning two years before release, the Nooro Knee Massager incorporates three targeted therapies: red light therapy, heat therapy, and massage therapy. The combination of these therapies sets it apart as a professionally proven choice for pain management, relieving joint pain and promoting overall joint health. The Nooro Knee Massager's 3-in-1 technology, encompassing high-frequency vibrations, heat therapy, and targeted design, delivers precise and effective knee massage. Designed to avoid the situation and alleviate joint pain, this innovative device has undergone thorough testing to ensure long-lasting relief with just a few applications. Is Nooro Knee Massager Safe For Use? The Nooro Knee Massager has achieved the esteemed status of being FDA-approved as a Class II medical device. This classification places it in the category of devices that are considered safe and effective for their intended use. The rigorous evaluation process conducted by the FDA adds a layer of credibility to the massager, offering users the assurance that it meets stringent standards for safety and performance. One of the key takeaways from Nooro Knee Massager's FDA approval is its safety for universal use. As a Class II medical device, it has been deemed safe for use by individuals across various demographics. This inclusivity ensures that people of all ages and backgrounds can confidently incorporate the Nooro Knee Massager into their wellness routines. The safety certification doesn't just stop at individual usage – it extends to the massager's adaptability to different environments. Whether you're at home, in the office, or on the go, the Nooro Knee Massager is designed to provide a safe and effective solution for knee pain relief. This versatility underscores its commitment to enhancing well-being without compromising safety standards. FDA approval for the Nooro Knee Massager removes potential barriers for individuals seeking a reliable and safe solution for knee discomfort. It signifies that the device has undergone thorough testing and meets the FDA's stringent criteria for safety and efficacy. Pros and Cons of Nooro Knee Massager Pros: (Nooro Knee Massager Reviews Consumer Reports and Complaints On Amazon) Effective triple therapy – Red Light, Heat, and Massage. FDA-approved as a Class II medical device. Versatile and portable design for use anywhere. Non-invasive alternative to surgeries. Affordable compared to other knee pain solutions. Suitable for various knee sizes. Wirelessly rechargeable for convenience. Cons: (Nooro Knee Reviews) May not provide the same results for everyone. Requires consistent use for optimal results. Availability may be subject to demand on the official website. May not replace the need for professional medical advice. Effectiveness may vary based on individual conditions. Price Of Nooro Knee Massager And Where To Buy The Nooro Knee Massager can be gotten directly from the official website at the following prices: 1 Nooro Knee Massager costs $179.95 2 Nooro Knee Massagers cost $169.95 each 3 Nooro Knee Massagers cost $159.95 each 4x Nooro Knee Massagers cost $149.95 each 6x Nooro Knee Massagers cost $139.95 each CLICK HERE NOW TO GET THE NOORO KNEE MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE How To Use And Care for Your Nooro Knee Massager? Using Your Nooro Knee Massager: Positioning: Place the Nooro Knee Massager on the affected knee, ensuring a snug fit with the adjustable straps. The device is designed for easy application, allowing you to focus the therapeutic effects precisely. Powering On: Press the "on" button to activate the massager. The user-friendly design ensures a straightforward operation, allowing you to initiate a 15-minute targeted therapy session with ease. Customization: Adjust the settings based on your preferences and therapeutic needs. The Nooro Knee Massager is designed for versatility, allowing you to tailor the experience to your unique requirements. Relax and Enjoy: Sit back and relax as the triple therapy – Red Light, Heat, and Massage – works to alleviate knee discomfort. Take advantage of this time to unwind and experience the soothing benefits of the Nooro Knee Massager. Taking Care of Your Nooro Knee Massager: Cleaning: Use a soft, damp cloth to clean the surface of the massager. Avoid harsh chemicals or abrasive materials to prevent damage to the device. Storage: Store the Nooro Knee Massager in a cool, dry place when not in use. Keep it away from direct sunlight and extreme temperatures. Charging: Charge the massager wirelessly using the provided charging cable. Ensure the device is fully charged before each use for optimal performance. Battery Maintenance: To prolong the battery life, avoid completely draining the battery before recharging. Charge the Nooro Knee Massager regularly, especially if it hasn't been used for an extended period. Avoid Submerging: The Nooro Knee Massager is not waterproof. Avoid submerging it in water or exposing it to excessive moisture. Handle with Care: While the Nooro Knee Massager is designed for durability, handle it with care to avoid unnecessary impact or stress on the device. Regular Checkups: Periodically check the device for any signs of wear or damage. If you notice any issues, contact the manufacturer for guidance on maintenance or potential repairs. Final Verdict On Nooro Knee Massager Reviews The final verdict on Nooro Knee Massager is a positive one, backed by its innovative design, FDA approval, and positive user reviews. The device employs a triple-therapy approach, combining Red Light, Heat, and Massage therapies to address knee discomfort effectively. In conclusion, Nooro Knee Massager appears to be a legitimate and effective solution for individuals dealing with knee discomfort. Its innovative approach, positive user reviews, and FDA approval contribute to a favorable final verdict. As with any health-related product, individuals are encouraged to consult with healthcare professionals if they have specific concerns or conditions. CLICK HERE NOW TO GET THE NOORO KNEE MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Disclaimer: This article should not be mistaken as a substitute for medical advice. Individual results may vary, consult a healthcare professional before use. Contact Details Reviewzenith Louis +44 7746 698754 Apexreviews154@gmail.com Company Website https://reviewzenith.com

December 16, 2023 08:30 AM Eastern Standard Time

Image

PathAI Introduces TumorDetect, an AI Solution to Automate Tumor Assessment and Case Prioritization for Anatomic Pathology Laboratories

PathAI

PathAI, a global leader in AI-powered pathology, today announced TumorDetect on AISight™, PathAI’s digital pathology image management system. TumorDetect is an AI-powered feature of AISight which automates the assessment and quantification of tumor across diverse tissue types. This product transforms pathology workflows by enabling case prioritization based on tumor content, helping pathologists to expedite case review, accelerate ordering of additional tests, and improving overall case turnaround time. As cancer incidence and corresponding cancer biopsy volumes continue to rise year-over-year, TumorDetect is designed to ensure that pathologists’ focus is guided to cases with highest likelihood of cancer with the goal of more rapid confirmation of tumor presence (for example, through downstream IHC assessment). In addition to identifying cases and slides likely to contain tumor, the product generates overlay visualizations and slide-level quantifications to facilitate pathologist review. PathAI will be expanding this pilot across its network of 50+ laboratory and early access partners across diverse tumor types globally. "Pathologists are facing increasing demands for faster case turnaround time, against a backdrop of increasing workload. TumorDetect is a game-changer in the field of pathology, empowering pathologists to efficiently prioritize cases based on tumor content," said Andy Beck, MD, PhD, Cofounder & CEO, PathAI. "Our AI-powered solution is designed to expedite the case review process but also facilitates faster turnaround times for labs." “AI-enabled assist tools such as TumorDetect can help pathologists perform important daily tasks – tumor detection and cellularity assessment, which are crucial for biomarker testing and precision medicine,” said Marilyn Bui, MD, PhD, Senior Member in the Departments of Pathology and Machine Learning at Moffitt Cancer Center and Research Institute. “I am excited about the potential for AI-assisted tumor assessment to augment pathologists’ effectiveness in delivering quality results and streamlining pathology workflows.” TumorDetect’s assessment and prioritization criteria are customizable, allowing pathologists to set personalized tumor content thresholds in line with their unique preferences and requirements. In addition to tumor cell quantification, TumorDetect also generates overlay visualizations highlighting hotspots of possible tumor on whole slide images (WSI). TumorDetect was developed on a dataset comprised of over 100,000 WSIs with over 6 million hand-drawn annotations from expert board-certified subspecialist pathologists, capturing the diversity of ways in which cancers appear in pathology WSIs. This feature, delivered through AISight, significantly aids pathologists during hotspot reviews, allowing for a more focused and targeted analysis of potentially cancerous regions. This announcement follows the launch of several AI algorithm products including AIM-PD-L1™ and AIM-HER2™ for reproducible biomarker and disease severity assessment, ArtifactDetect™ for automated quality control, and AIM-TumorCellularity™ (AIM-TC) for whole-slide level assessment of tumor cellularity. PathAI’s comprehensive suite of eight AI product offerings is designed to power pathologist decision making while optimizing laboratory efficiency. To learn more about AISight, PathAI’s image management system, or TumorDetect and its capabilities, please contact digitaldx@pathai.com About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. About AISight AISight, introduced earlier this year by PathAI, is a comprehensive digital pathology image management system, currently offered for Research Use Only. AISight provides best-in-class image and case management, ingestion, and viewing while seamlessly enabling access and deployment of AI applications. AISight can also be integrated bidirectionally with laboratory information systems for streamlined workflow adoption. Anatomic pathology laboratories of all sizes and specialties – including health systems, reference laboratories, independent pathology labs, and academic medical centers – may utilize AISight. TumorDetect, AISight, AIM-PD-L1, AIM-HER2, ArtifactDetect, and AIM-TumorCellularity are For Research Use Only. Not for use in diagnostic procedures. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

December 14, 2023 12:00 PM Eastern Standard Time

Image